Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;5(1):72-83.
doi: 10.1158/2326-6066.CIR-16-0194. Epub 2016 Dec 9.

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses

Takumi Kumai  1   2   3   4 , Sujin Lee  5   6 , Hyun-Il Cho  7 , Hussein Sultan  1 , Hiroya Kobayashi  3 , Yasuaki Harabuchi  4 , Esteban Celis  8
Affiliations

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses

Takumi Kumai et al. Cancer Immunol Res. 2017 Jan.

Abstract

Substantial evidence indicates that immunotherapy is a feasible and effective approach for the treatment of numerous types of cancer. Among various immunotherapy options, peptide vaccines to generate antitumor T cells appear as promising candidates, because of their cost effectiveness and ease of implementation. Nevertheless, most peptide vaccines are notorious for being weekly immunogenic and, thus, optimization of the vaccination strategy is essential to achieve therapeutic effectiveness. In addition, effective peptide vaccines must stimulate both CD8 cytotoxic and CD4 helper T lymphocytes. Our group has been successful in designing effective peptide vaccination strategies for inducing CD8 T-cell responses in mouse tumor models. Here, we describe a somewhat similar, but distinct, peptide vaccination strategy capable of generating vast CD4 T-cell responses by combining synthetic peptides with toll-like receptor (TLR) agonists and OX40/CD40 costimulation. This vaccination strategy was efficient in overcoming immune tolerance to a self-tumor-associated antigen and generated significant antitumor effects in a mouse model of malignant melanoma. The optimized peptide vaccine also allowed the expansion of adoptively transferred CD4 T cells without the need for lymphodepletion and IL2 administration, generating effective antimelanoma responses through the enhancement of proliferative and antiapoptotic activities of CD4 T cells. These results have practical implications in the design of more effective T-cell-based immunotherapies. Cancer Immunol Res; 5(1); 72-83. ©2016 AACR.

PubMed Disclaimer

Conflict of interest statement

of potential conflicts of interest Esteban Celis has filed patent applications based on the use of synthetic peptides and poly-IC combinatorial vaccines. The rights of the patent applications have been transferred to the Moffitt Cancer Center (Tampa, FL). All other authors declare no conflict of interest.

Figures

Figure 1
Figure 1. Combination of poly-IC and CD40 agonist with peptide vaccine induces robust CD4 T-cell responses
(A) Mice were immunized with Ova265-280 peptide on days 0 and 14. TriVax (poly-IC and CD40 mAb), TiterMax®, or CFA-IFA were used as adjuvants. TriVax was administered i.v. and TiterMax and CFA-IFA were injected s.c. EliSpot assay was done on day 21 using purified CD4 T cells from spleens (APCs: Ova265-280 peptide-pulsed LB27.4 cells). Less than 100 spots were observed using unpulsed APCs (E. Celis, unpublished observations). (B) Mice were vaccinated i.v. with Ova265-280 peptide with or w/o CD40 mAb, poly-IC, or with the combination of CD40 mAb and poly-IC (TriVax) on days 0 and 14. Mice were sacrificed on day 21, and the responses were measured as described in Fig. 1A. (C) Different doses of Ova265-280 peptide (10 μg, 50 μg, 100 μg, and 200 μg) were injected i.v. with TriVax protocol. EliSpot assay was done on day 21. (D) Mice were injected i.v. with peptide 2W1S (50 μg or 200 μg) combined with LPS or TriVax on days 0 and 14. Mice were sacrificed on day 6 after the boost and splenocytes (SP) and bone marrow cells (BM) were isolated for 2W1S/I-Ab tetramer staining. Splenocytes were incubated with peptide (1 μg/ml) (pep) in an intracellular IFNγ staining assay. Data shown are representative of three experiments with similar results. (E) Purified HTLs from splenocytes were cocultured with 2W1S peptide-pulsed LB27.4 cells for the EliSpot assay. Data represents the average of three experiments including 3–5 mice/experiment. Results are presented as mean ± SD. (*P < 0.05)
Figure 2
Figure 2. OX40 agonist synergizes with TriVax to further expand CD4 T cells
(A) Mice received TriVax (Ova265-280 peptide, poly-IC: 50 μg, and CD40 mAb) on days 0 and 14 and mice also received α4-1BB, αGITR, or αOX40 mAbs on days 0, 2, 12, and 14. Mice were sacrificed on day 21 and splenocytes were incubated with 1 μg/ml Ova265-280 peptide (+pep) or w/o peptide (−) in an intracellular cytokine-staining assay. The percentages of IFNγ+ CD4 T cells are shown in the upper right quadrants. The dot plots represent the results from one of the three separate experiments with similar results. (B) The number of IFNγ+ spots by CD4 T cells cocultured with Ova265-280 peptide-pulsed LB27.4 cells. Less than 100 spots were observed in the absence of peptide (E. Celis, unpublished observations). (C) Mice were vaccinated with TriVax (2W1S peptide, poly-IC, and CD40 mAb) combined with or w/o OX40 mAb (“prime & boost”: Day 0 and day 12, “boost”: day 12). The percentage of 2W1S tetramer+ cells in CD4 T cells was examined in blood or spleen. (D) The total number of 2W1S tetramer+ CD4 T cells in spleen. (*P < 0.05, n.s.: not significant). These experiments were repeated at least 2 times with similar results.
Figure 3
Figure 3. TLR7 agonist is a suitable adjuvant for CD4-targeted peptide vaccine, which requires type 1 IFN
(A) Mice were immunized on days 0, 14, and 65 (arrows) with TriVax (VV H3L273-286 peptide, CD40 mAb, and indicated TLR agonists; LPS, CpG, poly-IC, GDQ or no TLR agonist) combined with OX40 mAb. Antigen-specific CD4 T-cell responses were evaluated in blood using intracellular cytokine staining. (B) Mice received TriVax (2W1S peptide, CD40 mAb, and poly-IC or GDQ), with or w/o OX40 mAb on days 0 and 12. The percentages of 2W1S tetramer + CD4 T cells in blood on days 7 and 19 were examined by flow cytometry. (C) IFNαβ-KO and WT-B6 mice were vaccinated with TriVax (VV H3L273-286 peptide, Gardiquimod, CD40 mAb) and OX40 mAb on days 0 and 14, and responses were measured in blood on day 21. (D) IFNγ KO (GKO) mice and WT-B6 mice were vaccinated on day 0 and 14, and responses were measured in blood on day 21. (*P < 0.05, n.s.: not significant). These results represent example of three independent experiments.
Figure 4
Figure 4. CD4 T-cell responses to a non-immunogenic melanosomal antigen in wild-type or Trp1 KO mice
WT-B6 or Trp1-KO mice received TriVax (Trp1113-127 peptide, GDQ, and αCD40 mAb) and αOX40 mAb on days 0 and 12. (A) Splenocytes were harvested on day 19 and were stimulated with Trp1113-127 peptide (1 μg/ml) in intracellular cytokine staining assay. (B) EliSpot assay and (C) flow cytometry-based cytotoxicity assays were performed using purified CD4 T cells from splenocytes. (D) WT-B6 mice received TriVax and αOX40 mAb on days 0 and 12, mice were sacrificed on day 31 and splenocytes were used in intracellular cytokine staining assays; (*P < 0.05). These experiments were repeated 3 times with similar results.
Figure 5
Figure 5. Endogenous CD4 T cells induced by TriVax/OX40 have direct antitumor activity
(A and B) WT-B6 mice (10 per group) were inoculated subcutaneously on day 0 with 3 x 105 B16F10 melanoma cells. Mice were untreated (No Vac), received a control vaccine (mock Vac: GDQ and CD40 mAb) or TriVax with Trp1113-127 peptide, GDQ and CD40 mAb and OX40 mAb on days 3 and 15 (Vac). Tumor size (A) and the percent survival (time to euthanasia) of mice (B) are shown. Results are presented as mean ± SD. Individual tumor growth curves for each group are also presented. (C and D) WT-B6 mice (10 per group) were inoculated subcutaneously on day 0 with 3 x 105 B16F10 melanoma cells. Mice were untreated, received TriVax with Trp1113-127 peptide, GDQ, and CD40 mAb and OX40 mAb on days 3 and 15 (Vac). One group of vaccinated mice received αCD8 mAb on days 3, 5, 15, and 17 (Vac+CD8). The tumor size (C) and the percent survival of mice (D) are shown. Results are presented as mean ± SD. Arrows denote times of vaccination. These experiments were repeated 2 independent times and similar results were obtained
Figure 6
Figure 6. TriVax/OX40 expands adoptively transferred CD4 T cells without need of lymphodepletion
(A) B6 CD45.1 mice received 1 x 105 TRP1-TCR (CD45.2) splenocytes (~3 x 104 CD4 T cells) one day before the vaccination. The components of the vaccine (Trp1113-127 peptide with adjuvants) are indicated in the figure. The percentages of TRP1-TCR cells T cells (CD45.2+/CD4+) were measured in blood on day 7 after vaccination. Images of the representative results are shown. (B) Peptide-induced intracellular cytokine profiles of Trp1-TCR cells after vaccination. (C) Splenocytes were harvested from mice, which received 1 x 105 Trp1-TCR cells ACT (1 day before vaccination) and TriVax (Trp1113-127 peptide, GDQ, and CD40 mAb) and OX40 mAb on day 7 after vaccination. CD4 T cells were purified from the splenocytes and used in EliSpot assay with various target cells. (D) B6 mice received 1 x 105 TRP1-TCR (CD45.2) splenocytes (~3 x 104 CD4 T cells) one day before the TriVax with or without OX40 mAb agonist. Seven days later, the expression of Bcl-xL or Ki-67 in TRP1-TCR CD4 T cells from naïve TRP1-TCR or vaccinated mice were examined. (E) Splenocytes were harvested from mice, which received 1 x 105 Trp1-TCR cells ACT (1 day before vaccination) and TriVax (Trp1113-127 peptide, GDQ, and CD40 mAb) and OX40 mAb on day 7 after vaccination. CD4 T cells were purified from the splenocytes and used in EliSpot assay with various target cells; (*P < 0.05).
Figure 7
Figure 7. TriVax/OX40 potentiates the therapeutic antitumor effect of adoptively transferred CD4 T cells
(A and B) WT-B6 mice (10 per group) were inoculated subcutaneously on day 0 with 3 x 105 B16F10 melanoma cells. Mice received 1 x 105 TRP1-TCR cells on day 10 and TriVax (Trp1113-127 peptide, GDQ, and CD40 mAb) and OX40 mAb on day 11 (red arrows). Some mice received 2 injections of αPD-L1 following vaccination (black arrows). The size of tumor (A) and the percent survival of mice (B) are shown. Individual tumor growth curves for each group are also presented. (C) The percentages of TRP1-TCR cells TCR Vβ14+/CD4+) in blood after vaccine were measured in WT-B6 and Trp1-KO mice. The dotted line indicates the normal percentage of Vβ14+ CD4 T cells in WT-B6 mice. The blood was withdrawn on days 7, 12, and 14 after vaccination. Results are presented as mean ± SD; (*P < 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation eithout causing graft-versus-host disease. J Clin Oncol. 2016;34:1112–21. - PMC - PubMed
    1. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019–27. - PMC - PubMed
    1. Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin Cancer Res. 2016;22:3734–45. - PubMed
    1. Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014;20:4228–39. - PubMed
    1. Zhang S, Li W, Xia Z, Mao Y. CD4 T cell dependent tumor immunity stimulated by dendritic cell based vaccine. Biochem Biophys Res Commun. 2011;413:294–8. - PubMed

MeSH terms